Minesh D. Patel MD

Piedmont Cancer Institute - Newnan

775 Poplar Road
Suite 310
Newnan, GA 30265
770-251-2590 (p)
770-251-1490 (f)
www.piedmontcancerinstitute.com

driving directions

Clinical Trials
Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Cancer Type: Bladder Cancer

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Cancer Type: Breast Cancer

Study of Sacituzumab Govitecan-hziy and Pembrolizumab Versus Treatment of Physician's Choice in Patients With Triple Negative Breast Cancer Who Have Residual Invasive Disease After Surgery and Neoadjuvant Therapy (ASCENT-05/AFT-65 OptimICE-RD/GBG 119/NSABP B-63)
Cancer Type: Breast Cancer

A Phase III, Multisite, Randomized, Double-Blind Trial of BNT327 in Combination With Chemotherapy Versus Placebo With Chemotherapy in Patients With Previously Untreated Locally Recurrent Inoperable or Metastatic TNBC Determined Ineligible for PD(L)1 Therapy Based on PD-L1 Negative Disease
Cancer Type: Breast Cancer

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Cancer Type: Cervical Cancer

A Study of Amivantamab and FOLFIRI Versus Cetuximab/Bevacizumab and FOLFIRI in Participants With KRAS/NRAS and BRAF Wild-type Colorectal Cancer Who Have Previously Received Chemotherapy
Cancer Type: Colon/Rectal Cancer

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type: Kidney Cancer

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Cancer Type: Kidney Cancer

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Cancer Type: Liver Cancer / Hepatoblastoma

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Cancer Type: Liver Cancer / Hepatoblastoma

Phase III Study of Rilvegostomig in Combination With Bevacizumab With or Without Tremelimumab as First-line Treatment of Hepatocellular Carcinoma
Cancer Type: Liver Cancer / Hepatoblastoma

A Study of Amivantamab in Combination With Lazertinib, or Amivantamab in Combination With Platinum-Based Chemotherapy, for Common Epidermal Growth Factor Receptor (EGFR)-Mutated Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC = 50%) and Without Actionable Genomic Alterations
Cancer Type: Lung Cancer

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Cancer Type: Lung Cancer

Clinical Study of Ivonescimab for First-line Treatment of Metastatic NSCLC Patients With High PD-L1
Cancer Type: Lung Cancer

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Cancer Type: Lung Cancer

A Randomized, Controlled, Multi-Center Trial Evaluating Zongertinib as an Adjuvant Monotherapy Compared with Standard of Care in Patients with Early-Stage, Resectable Non-Small Cell Lung Cancer (Stage II-IIIB) Harboring Tyrosine Kinase Domain Activating HER2 Mutations
Cancer Type: Lung Cancer

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Cancer Type: Lung Cancer

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Cancer Type: Lung Cancer

A Study of Novel Combinations in Non-Small Cell Lung Cancer (NSCLC)
Cancer Type: Lung Cancer

A Phase 1/2a Study of DB-1311/BNT324 in Advanced/Metastatic Solid Tumors
Cancer Type: Melanoma

DB-1311 in Combination With BNT327 or DB-1305 in Advanced/Metastatic Solid Tumors
Cancer Type: Melanoma

MammaPrint, BluePrint, and Full-genome Data Linked With Clinical Data to Evaluate New Gene EXpression Profiles
Cancer Type: Unknown Primary

Phase III, Open-label, Study of First-line Dato-DXd in Combination With Rilvegostomig for Advanced Non-squamous NSCLC With High PD-L1 Expression (TC = 50%) and Without Actionable Genomic Alterations
Cancer Type: Unknown Primary

Study of Casdatifan and Cabozantinib Versus Placebo and Cabozantinib in Patients With Advanced Clear Cell Renal Cell Carcinoma
Cancer Type: Unknown Primary

A Study Evaluating the Efficacy and Safety of Divarasib and Pembrolizumab Versus Pembrolizumab and Pemetrexed and Carboplatin or Cisplatin in Participants With Previously Untreated, KRAS G12C-Mutated, Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer
Cancer Type: Unknown Primary

Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
Cancer Type: Unknown Primary

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Cancer Type: Unknown Primary

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Cancer Type: Ureter Cancer

Study of Datopotamab Deruxtecan Plus Carboplatin or Cisplatin Versus Gemcitabine Plus Carboplatin or Cisplatin in Participants With Locally Advanced or Metastatic Urothelial Carcinoma
Cancer Type: Urethral Cancer